Share Price and Basic Stock Data
Last Updated: January 3, 2026, 12:34 pm
| PEG Ratio | 0.89 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Syncom Formulations (India) Ltd operates in the pharmaceuticals sector, with its shares currently priced at ₹14.5 and a market capitalization of ₹1,359 Cr. The company has shown consistent revenue growth, with sales rising from ₹216 Cr in FY 2022 to ₹257 Cr in FY 2024, and projected to reach ₹461 Cr in FY 2025. This growth trajectory reflects a robust compound annual growth rate (CAGR) in sales, showcasing the company’s ability to expand its market presence. Quarterly sales trends indicate a steady increase, with sales reported at ₹61 Cr for March 2023, rising to ₹73 Cr in March 2024, and further projected at ₹148 Cr by March 2025. The operating profit margin (OPM) has also shown positive momentum, improving from 9% in FY 2022 to 12% in FY 2025, suggesting efficient cost management and operational efficacy. Overall, the company is positioned to capitalize on growing demand in the pharmaceutical industry.
Profitability and Efficiency Metrics
Profitability metrics for Syncom Formulations illustrate a healthy financial performance. The net profit for FY 2024 stood at ₹24 Cr, a notable increase from ₹20 Cr in FY 2023, reflecting a net profit margin of 9.35% in FY 2024. The return on equity (ROE) is reported at 15.5%, while the return on capital employed (ROCE) is at 18.6%, indicating effective utilization of shareholders’ funds and capital. The interest coverage ratio (ICR) is remarkably high at 82.74x, reflecting the company’s ability to meet its interest obligations comfortably, supported by the absence of borrowings as of the latest reporting period. The cash conversion cycle (CCC) stands at 83 days, suggesting that the company efficiently manages its working capital. Overall, these metrics position Syncom Formulations as a financially sound entity within the pharmaceutical sector, with strong profitability and operational efficiency.
Balance Sheet Strength and Financial Ratios
Syncom Formulations maintains a robust balance sheet, with total reserves of ₹282 Cr and zero borrowings, underscoring a solid capital structure. The company’s total assets are reported at ₹410 Cr, with a book value per share of ₹3.64. The debt-to-equity ratio remains extremely low at 0.01, reflecting a conservative financial policy that minimizes leverage. The current ratio is reported at 4.55, indicating strong liquidity and the ability to cover short-term obligations effectively. Financial ratios such as the price-to-book value (P/BV) at 4.52x suggest that the stock is trading at a premium compared to its book value, which is consistent with the high growth prospects of the company. These factors collectively contribute to a strong balance sheet, reinforcing investor confidence in Syncom Formulations’ financial health and operational sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syncom Formulations indicates a stable ownership structure, with promoters holding 50.57% of the equity. This level of promoter holding reflects strong management commitment and alignment of interests with shareholders. Foreign institutional investors (FIIs) have gradually increased their stake from 0% in March 2023 to 0.41% by June 2025, indicating growing interest from institutional investors. The total number of shareholders has also risen significantly, from 2,32,069 in December 2022 to 4,57,364 in September 2025, suggesting increased retail investor participation and confidence in the company’s growth prospects. The public holding stands at 49.33%, which indicates a healthy distribution of shares among retail investors, further enhancing market liquidity. This diverse shareholder base is a positive signal for ongoing investor confidence in Syncom Formulations.
Outlook, Risks, and Final Insight
Looking ahead, Syncom Formulations is well-positioned for growth, benefiting from increasing demand in the pharmaceutical sector. However, the company faces certain risks, including potential regulatory challenges and market competition which could impact margins. The absence of debt provides a cushion against financial risk, yet reliance on sales growth to drive profitability remains critical. Additionally, fluctuations in raw material prices could affect operating costs. While the company’s operational efficiency and strong balance sheet present strengths, careful navigation of these risks will be essential. If the company successfully leverages its operational strengths and continues to expand its market share, it could enhance shareholder value significantly. Conversely, failure to manage costs or adapt to market changes may hinder growth potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 54 | 57 | 61 | 59 | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 |
| Expenses | 48 | 50 | 51 | 55 | 53 | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 |
| Operating Profit | 3 | 4 | 6 | 6 | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 |
| OPM % | 7% | 8% | 10% | 10% | 10% | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% |
| Other Income | 3 | 3 | 2 | 7 | 2 | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 6 | 10 | 6 | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 |
| Tax % | 22% | 33% | 30% | 18% | 27% | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% |
| Net Profit | 4 | 4 | 4 | 8 | 4 | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 |
| EPS in Rs | 0.04 | 0.04 | 0.04 | 0.09 | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 |
Last Updated: August 20, 2025, 2:45 am
Below is a detailed analysis of the quarterly data for Syncom Formulations (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 117.00 Cr.. The value appears to be declining and may need further review. It has decreased from 148.00 Cr. (Mar 2025) to 117.00 Cr., marking a decrease of 31.00 Cr..
- For Expenses, as of Jun 2025, the value is 101.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 131.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 30.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 14.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Mar 2025) to 14.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Mar 2025) to 22.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.17. The value appears to be declining and may need further review. It has decreased from 0.19 (Mar 2025) to 0.17, marking a decrease of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 257 | 461 | 513 |
| Expenses | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 229 | 407 | 447 |
| Operating Profit | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 54 | 67 |
| OPM % | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 12% | 13% |
| Other Income | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 17 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 5 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 65 | 83 |
| Tax % | 33% | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | 24% | |
| Net Profit | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 49 | 63 |
| EPS in Rs | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.52 | 0.68 |
| Dividend Payout % | 17% | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 13% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.11% | 0.00% | 10.00% | -18.18% | 22.22% | 27.27% | 107.14% | -31.03% | 0.00% | 20.00% | 104.17% |
| Change in YoY Net Profit Growth (%) | 0.00% | -11.11% | 10.00% | -28.18% | 40.40% | 5.05% | 79.87% | -138.18% | 31.03% | 20.00% | 84.17% |
Syncom Formulations (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 18% |
| 3 Years: | 29% |
| TTM: | 73% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 35% |
| TTM: | 111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 59% |
| 3 Years: | 26% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:04 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 | 94 | 94 |
| Reserves | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 109 | 136 | 162 | 192 | 246 | 282 |
| Borrowings | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | 4 | 0 |
| Other Liabilities | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 42 | 28 | 38 | 33 | 66 | 74 |
| Total Liabilities | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 451 |
| Fixed Assets | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | 125 | 124 |
| CWIP | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 | 0 | 8 |
| Investments | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 | 93 | 148 |
| Other Assets | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | 192 | 171 |
| Total Assets | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 | 410 | 451 |
Below is a detailed analysis of the balance sheet data for Syncom Formulations (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 94.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 94.00 Cr..
- For Reserves, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 246.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 36.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 66.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 410.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 41.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 124.00 Cr.. The value appears to be declining and may need further review. It has decreased from 125.00 Cr. (Mar 2025) to 124.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 148.00 Cr.. The value appears strong and on an upward trend. It has increased from 93.00 Cr. (Mar 2025) to 148.00 Cr., marking an increase of 55.00 Cr..
- For Other Assets, as of Sep 2025, the value is 171.00 Cr.. The value appears to be declining and may need further review. It has decreased from 192.00 Cr. (Mar 2025) to 171.00 Cr., marking a decrease of 21.00 Cr..
- For Total Assets, as of Sep 2025, the value is 451.00 Cr.. The value appears strong and on an upward trend. It has increased from 410.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 41.00 Cr..
Notably, the Reserves (282.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 13.00 | 12.00 | 11.00 | 4.00 | 0.00 | 3.00 | 15.00 | -24.00 | -38.00 | -63.00 | -44.00 | 50.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 | 85 |
| Inventory Days | 36 | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 | 49 |
| Days Payable | 105 | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 | 51 |
| Cash Conversion Cycle | 1 | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 | 83 |
| Working Capital Days | 75 | 84 | 40 | 45 | 75 | 74 | 88 | 28 | 33 | -4 | 51 | 95 |
| ROCE % | 15% | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 5,387 | 0.09 | 0.01 | 5,387 | 2025-04-22 16:59:38 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 17 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.26 | 0.13 |
| Diluted EPS (Rs.) | 0.57 | 0.34 | 0.24 | 0.24 | 0.13 |
| Cash EPS (Rs.) | 0.58 | 0.31 | 0.26 | 0.27 | 0.17 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3.64 | 3.07 | 2.72 | 2.58 | 1.50 |
| Revenue From Operations / Share (Rs.) | 4.95 | 2.80 | 2.39 | 2.55 | 2.37 |
| PBDIT / Share (Rs.) | 0.76 | 0.45 | 0.36 | 0.37 | 0.24 |
| PBIT / Share (Rs.) | 0.70 | 0.40 | 0.31 | 0.32 | 0.20 |
| PBT / Share (Rs.) | 0.69 | 0.36 | 0.28 | 0.30 | 0.20 |
| Net Profit / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| NP After MI And SOA / Share (Rs.) | 0.52 | 0.26 | 0.21 | 0.22 | 0.13 |
| PBDIT Margin (%) | 15.39 | 16.39 | 15.26 | 14.58 | 10.43 |
| PBIT Margin (%) | 14.27 | 14.59 | 13.23 | 12.78 | 8.74 |
| PBT Margin (%) | 14.08 | 12.89 | 11.84 | 11.91 | 8.59 |
| Net Profit Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| NP After MI And SOA Margin (%) | 10.63 | 9.61 | 8.94 | 9.00 | 5.69 |
| Return on Networth / Equity (%) | 14.44 | 8.78 | 7.83 | 8.90 | 8.97 |
| Return on Capital Employeed (%) | 18.75 | 12.89 | 11.21 | 12.20 | 12.92 |
| Return On Assets (%) | 11.96 | 6.25 | 5.31 | 6.42 | 5.84 |
| Total Debt / Equity (X) | 0.01 | 0.25 | 0.32 | 0.26 | 0.10 |
| Asset Turnover Ratio (%) | 1.14 | 0.67 | 0.65 | 0.00 | 1.05 |
| Current Ratio (X) | 4.55 | 2.58 | 1.61 | 1.79 | 1.50 |
| Quick Ratio (X) | 3.85 | 2.38 | 1.42 | 1.54 | 1.32 |
| Inventory Turnover Ratio (X) | 14.90 | 6.22 | 4.89 | 0.00 | 5.42 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 14.82 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 11.43 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.18 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 88.57 |
| Interest Coverage Ratio (X) | 82.74 | 9.65 | 10.93 | 16.62 | 68.46 |
| Interest Coverage Ratio (Post Tax) (X) | 58.15 | 6.66 | 7.41 | 11.25 | 38.42 |
| Enterprise Value (Cr.) | 1550.17 | 1055.54 | 629.15 | 974.19 | 159.72 |
| EV / Net Operating Revenue (X) | 3.33 | 4.01 | 2.81 | 4.43 | 0.86 |
| EV / EBITDA (X) | 21.66 | 24.45 | 18.38 | 30.42 | 8.28 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.17 |
| Price / BV (X) | 4.52 | 3.65 | 2.17 | 4.13 | 1.31 |
| Price / Net Operating Revenue (X) | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.06 |
After reviewing the key financial ratios for Syncom Formulations (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 5. It has increased from 0.34 (Mar 24) to 0.57, marking an increase of 0.23.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 3. It has increased from 0.31 (Mar 24) to 0.58, marking an increase of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 3.64. It has increased from 3.07 (Mar 24) to 3.64, marking an increase of 0.57.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 4.95. It has increased from 2.80 (Mar 24) to 4.95, marking an increase of 2.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 2. It has increased from 0.45 (Mar 24) to 0.76, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.70. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.70, marking an increase of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.36 (Mar 24) to 0.69, marking an increase of 0.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 2. It has increased from 0.26 (Mar 24) to 0.52, marking an increase of 0.26.
- For PBDIT Margin (%), as of Mar 25, the value is 15.39. This value is within the healthy range. It has decreased from 16.39 (Mar 24) to 15.39, marking a decrease of 1.00.
- For PBIT Margin (%), as of Mar 25, the value is 14.27. This value is within the healthy range. It has decreased from 14.59 (Mar 24) to 14.27, marking a decrease of 0.32.
- For PBT Margin (%), as of Mar 25, the value is 14.08. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 14.08, marking an increase of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 10.63. This value exceeds the healthy maximum of 10. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has increased from 9.61 (Mar 24) to 10.63, marking an increase of 1.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 15. It has increased from 8.78 (Mar 24) to 14.44, marking an increase of 5.66.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.75. This value is within the healthy range. It has increased from 12.89 (Mar 24) to 18.75, marking an increase of 5.86.
- For Return On Assets (%), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from 6.25 (Mar 24) to 11.96, marking an increase of 5.71.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.01, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.14. It has increased from 0.67 (Mar 24) to 1.14, marking an increase of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.55. This value exceeds the healthy maximum of 3. It has increased from 2.58 (Mar 24) to 4.55, marking an increase of 1.97.
- For Quick Ratio (X), as of Mar 25, the value is 3.85. This value exceeds the healthy maximum of 2. It has increased from 2.38 (Mar 24) to 3.85, marking an increase of 1.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.90. This value exceeds the healthy maximum of 8. It has increased from 6.22 (Mar 24) to 14.90, marking an increase of 8.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 82.74. This value is within the healthy range. It has increased from 9.65 (Mar 24) to 82.74, marking an increase of 73.09.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 58.15. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 58.15, marking an increase of 51.49.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,550.17. It has increased from 1,055.54 (Mar 24) to 1,550.17, marking an increase of 494.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 24) to 3.33, marking a decrease of 0.68.
- For EV / EBITDA (X), as of Mar 25, the value is 21.66. This value exceeds the healthy maximum of 15. It has decreased from 24.45 (Mar 24) to 21.66, marking a decrease of 2.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 4.52. This value exceeds the healthy maximum of 3. It has increased from 3.65 (Mar 24) to 4.52, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 3.99 (Mar 24) to 3.33, marking a decrease of 0.66.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syncom Formulations (India) Ltd:
- Net Profit Margin: 10.63%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.75% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.44% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 58.15
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.6 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.63%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 7, Niraj Industrial Estate, Off Mahakali Caves Road, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ankit Kedarmal Bankda | Executive Chairman & Whole-time Director |
| Mr. Vijay Shankarlal Bankda | Managing Director |
| Mr. Kedarmal Shankarlal Bankda | Whole Time Director |
| Mrs. Ruchi Jindal | Independent Woman Director |
| Mr. Ritesh Kumar Lunkad | Independent Director |
| Mr. Ankit Jain | Independent Director |
FAQ
What is the intrinsic value of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's intrinsic value (as of 04 January 2026) is ₹10.93 which is 24.62% lower the current market price of ₹14.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,359 Cr. market cap, FY2025-2026 high/low of ₹23.5/14.0, reserves of ₹282 Cr, and liabilities of ₹451 Cr.
What is the Market Cap of Syncom Formulations (India) Ltd?
The Market Cap of Syncom Formulations (India) Ltd is 1,359 Cr..
What is the current Stock Price of Syncom Formulations (India) Ltd as on 04 January 2026?
The current stock price of Syncom Formulations (India) Ltd as on 04 January 2026 is ₹14.5.
What is the High / Low of Syncom Formulations (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syncom Formulations (India) Ltd stocks is ₹23.5/14.0.
What is the Stock P/E of Syncom Formulations (India) Ltd?
The Stock P/E of Syncom Formulations (India) Ltd is 21.6.
What is the Book Value of Syncom Formulations (India) Ltd?
The Book Value of Syncom Formulations (India) Ltd is 4.00.
What is the Dividend Yield of Syncom Formulations (India) Ltd?
The Dividend Yield of Syncom Formulations (India) Ltd is 0.00 %.
What is the ROCE of Syncom Formulations (India) Ltd?
The ROCE of Syncom Formulations (India) Ltd is 18.6 %.
What is the ROE of Syncom Formulations (India) Ltd?
The ROE of Syncom Formulations (India) Ltd is 15.5 %.
What is the Face Value of Syncom Formulations (India) Ltd?
The Face Value of Syncom Formulations (India) Ltd is 1.00.